Related Experiment Video
Updated: Jun 19, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Perinatal mood and anxiety diagnoses and treatment increased among medicaid births, 2017-2021
Kara Zivin1,2,3, Andrea Pangori4, Anca Tilea4
1Department of Psychiatry, Michigan Medicine, 2800 Plymouth Road, Building 16, Ann Arbor, MI, 48109, USA. kzivin@umich.edu.
Despite funding the most births in the United States (US), we know little about basic patterns and trends of mental health conditions among Medicaid-insured women during pregnancy and after delivery. We sought to characterize the prevalence of diagnosis and treatment for perinatal mood and anxiety disorders (PMAD) among women with Medicaid health insurance coverage. We conducted serial, cross-sectional analyses of women with live-birth deliveries during 2017-2021 using Transformed Medicaid Statistical Information System (T-MSIS) claims. To construct state-specific PMAD diagnosis and treatment trajectories including antidepressant prescriptions and psychotherapy visits, we examined geographic variations by state and year among reproductive aged women. In a national cohort of 4,579,289 women with Medicaid and a live birth, 635,785 (13.88%) had a PMAD diagnosis during the study period. Perinatal women in all age, race, ethnicity, geographic regions, comorbidity burdens, and all but one state experienced growth in PMAD diagnoses. Substantial variation occurred among states for antidepressant use, while national trends remained stable. Characterizing PMAD diagnosis and treatment patterns represents an important public health contribution. Future research should aim to better understand factors underlying variation in PMAD diagnoses and treatment across subgroups and geographic areas.
Despite funding the most births in the United States (US), we know little about basic patterns and trends of mental health conditions among Medicaid-insured women during pregnancy and after delivery. We sought to characterize the prevalence of diagnosis and treatment for perinatal mood and anxiety disorders (PMAD) among women with Medicaid health insurance coverage. We conducted serial, cross-sectional analyses of women with live-birth deliveries during 2017-2021 using Transformed Medicaid Statistical Information System (T-MSIS) claims. To construct state-specific PMAD diagnosis and treatment trajectories including antidepressant prescriptions and psychotherapy visits, we examined geographic variations by state and year among reproductive aged women. In a national cohort of 4,579,289 women with Medicaid and a live birth, 635,785 (13.88%) had a PMAD diagnosis during the study period. Perinatal women in all age, race, ethnicity, geographic regions, comorbidity burdens, and all but one state experienced growth in PMAD diagnoses. Substantial variation occurred among states for antidepressant use, while national trends remained stable. Characterizing PMAD diagnosis and treatment patterns represents an important public health contribution. Future research should aim to better understand factors underlying variation in PMAD diagnoses and treatment across subgroups and geographic areas.
Related Concept Videos
Diagnostic and Statistical Manual of Mental Disorders (DSM)
Bipolar Disorder
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Socioemotional Development during Infancy
Primary Temperament Types
Stella Chess...
Drug Therapy
Antianxiety Medications
Mania and Antimanic Drugs: Overview
